Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
Five years ago, large numbers of farmers in central China began falling victim to an mysterious disease marked by high fever, gastrointestinal disorder and an appalling mortality rate - as high as 30 percent in initial reports. Investigators from the Chinese Center for Disease Control and Prevention hurried to the scene of the outbreak. On the basis of DNA evidence, they quickly concluded that it had been caused by human granulocytic anaplasmosis, a bacteria transmitted by tick bites.
The natural killer cells of our immune defense are activated for an extended period after the acute infection, which challenges the prevailing view that the elevation and activation of cells quickly pass.
Scientists from Thailand have successfully produced the world’s first dengue hemorrhagic fever vaccine and will allow the private sector improve it for the effective treatment of patients. The Thailand Ministry of Science and Technology has introduced the world’s first live attenuated dengue hemorrhagic fever vaccine.
NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health agenda.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today that it has signed a collaboration agreement with Janssen Pharmaceutica N.V. for the discovery and development of drugs for the prophylaxis and treatment of dengue virus infection.
India could soon become a site for clinical trials to evaluate the effectiveness of a dengue vaccine, the Times of India reports. According to the drug controller general of India, vaccine maker Sanofi Pasteur recently submitted a proposal to test the vaccine to the country.
The International Vaccine Institute today announced the launch of the Dengue Vaccine Initiative, in collaboration with the Sabin Vaccine Institute, the Johns Hopkins University, and the World Health Organization, to support development of vaccines to control dengue fever, a widespread and expanding hemorrhagic fever that is endemic in most tropical and subtropical regions of the world.
Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.
Ebola, a virus that causes deadly hemorrhagic fever in humans, has no known cure or vaccine. But a new study by University of Illinois at Chicago scientists has uncovered a family of small molecules which appear to bind to the virus's outer protein coat and may inhibit its entry into human cells.
Using chemical compounds found in a Japanese plant as a lead and the clever application of ultraviolet light, a Scripps Research Institute team has created a unique library of dozens of synthetic compounds to test for biomedical potential. Already, one of the compounds has shown great promise in inhibiting replication of HIV particles and fighting inflammation.
Guidance about pre-travel precautions and preventive measures are highlighted in the December 1, 2010 issue of Clinical Infectious Diseases, written by clinicians and researchers at the Uniformed Services University of the Health Sciences and their partners from the University of Texas Health Sciences Center, Naval Medical Research Center and others.
Boston University researchers have developed a simple diagnostic tool that can quickly identify dangerous viruses like Ebola and Marburg. The biosensor, which is the size of a quarter and can detect viruses in a blood sample, could be used in developing nations, airports and other places where natural or man-made outbreaks could erupt.
Scientists at Emory University and the University of St. Andrews have solved the structure of a key protein from Lassa virus, which is endemic to West Africa and can cause a deadly hemorrhagic fever.
NPR's Shots blog examines progress in the search for a vaccine to protect against the dengue virus. WHO estimates that 2.5 billion people worldwide are at risk of getting dengue, and most of them are in Asia and Latin America, the blog writes.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate, entered its first phase 3 clinical study in Australia.
Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that it has been awarded a $4.99 million contract to assist the U.S. Army Medical Research Institute for Infectious Diseases in its vaccine development efforts.
NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.
Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.
Australians researchers are moving towards producing the first ever vaccine for dengue fever, the potentially life-threatening infection spread by mosquitoes in the tropics. At present late stage clinical trials are underway for a vaccine that would protect against all four known strains of the disease. Participants are now being recruited in Perth, Adelaide and Brisbane.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.